Review ArticleReview Article
Tumor Necrosis Factor-Induced Cerebral Insulin Resistance in Alzheimer's Disease Links Numerous Treatment Rationales
Ian Clark, Craig Atwood, Richard Bowen, Gilberto Paz-Filho and Bryce Vissel
David R. Sibley, ASSOCIATE EDITOR
Pharmacological Reviews October 2012, 64 (4) 1004-1026; DOI: https://doi.org/10.1124/pr.112.005850
Ian Clark
Research School of Biology, Australian National University, Canberra, Australia (I.C.); Department of Medicine, University of Wisconsin-Madison School of Medicine and Public Health, Madison, Wisconsin (C.A.); School of Exercise, Biomedical and Health Sciences, Edith Cowan University, Joondalup, Australia (C.A.); OTB Research, Charleston, South Carolina (R.B.); John Curtin School of Medical Research, Australian National University, Canberra, Australia (G.P.-F.); and the Neurodegeneration Research Group, Garvan Institute of Medical Research, Sydney, Australia (B.V.)
Craig Atwood
Research School of Biology, Australian National University, Canberra, Australia (I.C.); Department of Medicine, University of Wisconsin-Madison School of Medicine and Public Health, Madison, Wisconsin (C.A.); School of Exercise, Biomedical and Health Sciences, Edith Cowan University, Joondalup, Australia (C.A.); OTB Research, Charleston, South Carolina (R.B.); John Curtin School of Medical Research, Australian National University, Canberra, Australia (G.P.-F.); and the Neurodegeneration Research Group, Garvan Institute of Medical Research, Sydney, Australia (B.V.)
Richard Bowen
Research School of Biology, Australian National University, Canberra, Australia (I.C.); Department of Medicine, University of Wisconsin-Madison School of Medicine and Public Health, Madison, Wisconsin (C.A.); School of Exercise, Biomedical and Health Sciences, Edith Cowan University, Joondalup, Australia (C.A.); OTB Research, Charleston, South Carolina (R.B.); John Curtin School of Medical Research, Australian National University, Canberra, Australia (G.P.-F.); and the Neurodegeneration Research Group, Garvan Institute of Medical Research, Sydney, Australia (B.V.)
Gilberto Paz-Filho
Research School of Biology, Australian National University, Canberra, Australia (I.C.); Department of Medicine, University of Wisconsin-Madison School of Medicine and Public Health, Madison, Wisconsin (C.A.); School of Exercise, Biomedical and Health Sciences, Edith Cowan University, Joondalup, Australia (C.A.); OTB Research, Charleston, South Carolina (R.B.); John Curtin School of Medical Research, Australian National University, Canberra, Australia (G.P.-F.); and the Neurodegeneration Research Group, Garvan Institute of Medical Research, Sydney, Australia (B.V.)
Bryce Vissel
Research School of Biology, Australian National University, Canberra, Australia (I.C.); Department of Medicine, University of Wisconsin-Madison School of Medicine and Public Health, Madison, Wisconsin (C.A.); School of Exercise, Biomedical and Health Sciences, Edith Cowan University, Joondalup, Australia (C.A.); OTB Research, Charleston, South Carolina (R.B.); John Curtin School of Medical Research, Australian National University, Canberra, Australia (G.P.-F.); and the Neurodegeneration Research Group, Garvan Institute of Medical Research, Sydney, Australia (B.V.)
David R. Sibley
Research School of Biology, Australian National University, Canberra, Australia (I.C.); Department of Medicine, University of Wisconsin-Madison School of Medicine and Public Health, Madison, Wisconsin (C.A.); School of Exercise, Biomedical and Health Sciences, Edith Cowan University, Joondalup, Australia (C.A.); OTB Research, Charleston, South Carolina (R.B.); John Curtin School of Medical Research, Australian National University, Canberra, Australia (G.P.-F.); and the Neurodegeneration Research Group, Garvan Institute of Medical Research, Sydney, Australia (B.V.)
Roles: ASSOCIATE EDITOR

Submit a Response to This Article
Jump to comment:
No eLetters have been published for this article.
In this issue
Review ArticleReview Article
TNF CAUSES INSULIN RESISTANCE: IMPLICATIONS FOR AD
Ian Clark, Craig Atwood, Richard Bowen, Gilberto Paz-Filho and Bryce Vissel
Pharmacological Reviews October 1, 2012, 64 (4) 1004-1026; DOI: https://doi.org/10.1124/pr.112.005850
Jump to section
- Article
- Abstract
- I. Introduction
- II. Gonadotropins, Sex Steroids, Tumor Necrosis Factor, and Alzheimer's Disease
- III. Tumor Necrosis Factor and Alzheimer's Disease
- IV. Tumor Necrosis Factor, Amyloid β, and τ
- V. Insulin
- VI. Tumor Necrosis Factor and Glycogen Synthase Kinase-3
- VII. Tumor Necrosis Factor and Mitochondrial Dysfunction
- VIII. Tumor Necrosis Factor and Progenitor Cells
- IX. Streptozotocin
- X. The Broader Picture—Stroke, Traumatic Brain Injury, and Infectious Disease
- XI. Therapeutic Implications
- XII. Conclusions
- Authorship Contributions
- Footnotes
- References
- Figures & Data
- Info & Metrics
- eLetters
Related Articles
Cited By...
More in this TOC Section
Similar Articles
Advertisement